2012 - According to the 2012 bioequivalent study comparing between Teno-EM 300/200 and original medication,
the conclusion was that the Teno-Em 300/200mg tablets manufactured by GPO Thailand when compared with the reference product Original Medication 300/200mg tablets manufactured in Germany met the bioequivalence criteria (90% confident interval for the ratio of geometric least squares means within 80.00-125.00%) with respect to the rate and extent of absorption of tenofovir and emtricitabine. Therefore, two formulations were bioequivalent and can be used interchangeably.
2013 - The Bangkok Tenofovir Study (Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand : a randomised, double-blind, placebo-controlled phase 3 trial) was published on THE LANCET.
2014 - Thailand National Guidelines on HIV/AIDS Treatment and Prevention 2014 has listed Teno-EM 300/200 as medication to be used for HIV prevention (Pre-Exposure Prophylaxis) and treatment of HIV infection.
2016 - 56 Dean street / IwantPrEPnow.co.uk has purchased Teno-EM from Pulse Clinic and has tested the medication by taking a blood test which detects the levels of active drug Tenofovir (TDF) and Emtricitabine (FTC) (PrEP protection) in the blood, this test is known as Therapeutic Drug Monitoring, or TDM, of course they have had satisfactory results of Teno-Em.
2017- THAI AIDS SOCIETY has launched Thailand National Guidelines on HIV/AIDS Treatment and Prevention 2017 and has included Teno-Em as HIV prevention provided by all national government hospitals (Chapter 3, page 346)
Manufacturer // Distributor // Marketer : The Government Pharmaceutical Organization (GPO)
Contents : Tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg
Indications / Uses : Prevention and treatment of HIV-1 infection in combination w/ other antiretroviral agents eg, NNRTIs or PIs.
Dosage / Direction for Use : Adult 1 tab once daily.
Administration : May be taken with or without food: Take consistently either always w/ or always w/o food.
Read about Teno-EM and its 2012 BIOEQUIVALENT STUDY HERE